News & Events

Press Release

TLC to Present at Baird’s 2020 Global Healthcare Conference

September 3, 2020 at 5:00 AM EDT

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 03, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that George Yeh, President of TLC, will be presenting the latest updates on the company in a fireside chat with Madhu Kumar, Senior Research Analyst, at Baird’s 2020 Global Healthcare Conference on Wednesday, September 9, 2020 at 8:30am ET.

The 30-minute fireside chat will include a company overview followed by a Q&A session. During the conference, which is taking place virtually September 9-10, 2020, TLC will also be participating in one-on-one sessions. While the fireside chat is only accessible to Baird clients registered for the event, a corporate presentation entailing the updates will be available on the company’s website at www.tlcbio.com under the Investors section.

About TLC

TLC (NASDAQ: TLC, TWO: 4152) is a clinical-stage specialty pharmaceutical company dedicated to the research and development of a diverse, wholly owned portfolio of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD™), including BioSeizer® sustained release technology and NanoX™ active drug loading technology, which are versatile in the choice of active pharmaceutical ingredients and scalable in manufacturing. 

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future performance and involve a number of risks, assumptions, uncertainties and factors, including risks that the outcome of any clinical trial is inherently uncertain and product candidates may prove to be unsafe or ineffective, or may not achieve commercial approval.  Other risks are described in the Risk Factors section of TLC’s annual report on Form 20-F for the year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on TLC’s expectations and assumptions as of the date of this press release. Actual results may differ materially from these forward-looking statements. Except as required by law, TLC expressly disclaims any responsibility to update any forward-looking statement contained herein, whether as a result of new information, future events or otherwise.

 

 
Contact

Dawn Chi
Corporate Communications
dawn@tlcbio.com

TLC_Tagline.png

 

Source: TLC